Ashland
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty ...
Latest News
17 hours ago · businesswire.com
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical ModelsEMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for cancer and autoimmune diseases, today highlighted preclinical findings from an abstract accepted for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans, Louisiana. The research, described in.
3 days ago · seekingalpha.com
Ashland: Focus On FY 2027 Financial Improvement And Potential SaleAshland Inc. remains a "Buy," considering its positive financial outlook and interest from possible acquirers. ASH's 4QFY26 revenue and EBITDA largely met expectations; the company is anticipating a turnaround in FY2027 on the back of pricing upside potential and the conclusion of cost restructuring initiatives. According to recent news reports, there are both industry players and private equity firms interested in taking over Ashland.
5 days ago · globenewswire.com
Ashland board authorizes quarterly dividendWILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.42 cents per share on the company's common stock.
6 days ago · zacks.com
ASH Q4 Earnings Miss Estimates Despite Strong Segment GrowthAshland's Q4 fiscal 2026 earnings and sales miss estimates despite volume growth and strong Personal Care demand. The company projects higher sales for fiscal 2027.
12 days ago · globenewswire.com
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and ExpositionBRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that new and updated clinical data from its ongoing Phase 1a/1b study evaluating bexobrutideg (NX-5948), the Company's investigational oral Bruton's tyrosine kinase (BTK) degrader, will be presented in a poster session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15, 2026 in New Orleans, Louisiana.
12 days ago · marketbeat.com
What Ashland (ASH) Said on Its Q4 Earnings CallAshland NYSE: ASH reported higher sales and adjusted earnings for its fiscal fourth quarter, as growth in pharmaceutical and personal care products helped offset weaker manufacturing productivity in Specialty Additives.
13 days ago · globenewswire.com
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual MeetingFirst interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML
13 days ago · globenewswire.com
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 12-15, 2026, in New Orleans, Louisiana.
13 days ago · businesswire.com
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026). These latest clinical milestones demonstrate transformative progress across Gilead and Kite's pipeline and portfolio, from new data for the investigational anitocabtagene autoleucel (anito-cel) in relapsed or.
13 days ago · prnewswire.com
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell DiseaseThe three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across cancer and nonmalignant diseases Phase 1b/2 trial evaluates targeted immune conditioning with Iomab-ACT before standard commercial CD19-directed CAR T-cell therapy Memorial Sloan Kettering Cancer Center study demonstrates promise of Iomab-ACT as targeted conditioning agent before CAR T-cell therapy, with a focus on CAR T-cell expansion, immune cell depletion and treatment-related toxicities Clinical experience in severe sickle cell disease evaluates Iomab-ACT-based conditioning to support donor engraftment without conventional chemotherapy NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced the release of three abstracts for the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. The abstracts highlight clinical findings and continued development of Iomab-ACT, the Company's investigational CD45-targeted radioimmunotherapy, as a conditioning approach before CAR T-cell therapy and allogeneic stem cell transplantation for severe sickle cell disease.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ASH